Drawing for PHARMA COMPLETE

USPTO serial 76335793

PHARMA COMPLETE

Reviewed by CopyMark Law Group

Reg. 2777306Status 710
Filing date
Status date
Registration date
Oct 28, 2003
Examiner
SAITO, KIM
Law office
SCANNING ON DEMAND

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PHARMA COMPLETE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Morland C. Fischer

MORLAND C FISCHER2030 MAIN ST STE 1050IRVINE, CA 92614UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Mail order catalog services in the field of medical equipment and supplies, medications, orthotics, prosthetics, muscle stimulators and bone growth stimulatorsSECTION 8 - CANCELLEDJun 1, 1998
036insurance claims administration, namely, billing insurance companies for the services of contractors to modify homes for chronically ill and catastrophically injured patients and workersSECTION 8 - CANCELLEDJun 1, 1998
044Providing medical care and home healthcare services to chronically ill and catastrophically injured patients and workers following hospital discharge; namely IV therapy, dispensing medications, nursing care, and respiratory therapySECTION 8 - CANCELLEDJun 1, 1998

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 5, 2010C8..CANCELLED SEC. 8 (6-YR)—
Jun 4, 2008CFITCASE FILE IN TICRS—
Dec 5, 2007ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 28, 2003R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 5, 2003PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 16, 2003NPUBNOTICE OF PUBLICATION—
Jun 12, 2003CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 6, 2003CNEAEXAMINERS AMENDMENT MAILED—
Feb 24, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 24, 2003MAILPAPER RECEIVED—
Aug 22, 2002CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 20, 2002CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 20, 2002MAILPAPER RECEIVED—
Jan 29, 2002CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 16, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance